comparemela.com

Latest Breaking News On - பெட்டி எச்சரிக்கைகள் - Page 1 : comparemela.com

Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021

Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

California
United-states
Foster-city
American
Jacquie-ross
Brian-plummer
Nicole-rodriguez
Frank-duff
Prevention-research
Gilead-sciences
Gilead-sciences-inc
Nasdaq

Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Japan
Canada
United-kingdom
Switzerland
Jennifer-mcintyre
Lee-pasqualoni
Christopher-delorefice
Sarah-freeman
None-of-the-janssen-pharmaceutical-companies
Janssen-pharmaceuticals-inc
Janssen-research-development
Janssen-pharmaceutical-companies

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting News provided by Share this article Share this article INDIANAPOLIS, May 19, 2021 /PRNewswire/ New data from across Eli Lilly and Company s (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data include new analyses of Verzenio ® (abemaciclib) from the Phase 3 monarchE trial in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) with a high risk of recurrence who received neoadjuvant chemotherapy. In addition, the first clinical data from the Phase 1 study of Lilly s oral selective estrogen receptor degrader (SERD) will be presented at the meeting.

United-states
China
Chinese
American
Fabrice-andre
Fulvestrant-faslodex
Shao-zhimin
Torres-raquel
Eli-lilly
Deboras-bruno
Douglas-yee
Kevin-hern

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-states
China
Chinese
American
Fabrice-andre
Fulvestrant-faslodex
Shao-zhimin
Torres-raquel
Eli-lilly
Deboras-bruno
Douglas-yee
Kevin-hern

Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization

Share this article Share this article RARITAN, N.J., May 16, 2021 /PRNewswire/  The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO ® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiology s 70

Colorado
United-states
Americans
American
Marcp-bonaca
Jennifer-mcintyre
Lee-pasqualoni
Christopher-delorefice
Jennifer-silvent
American-heart-association
Division-of-cardiovascular-medicine
Janssen-pharmaceuticals-inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.